These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 8726042

  • 1. In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone.
    Oh JI, Paek KS, Ahn MJ, Kim MY, Hong CY, Kim IC, Kwak JH.
    Antimicrob Agents Chemother; 1996 Jun; 40(6):1564-8. PubMed ID: 8726042
    [Abstract] [Full Text] [Related]

  • 2. Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone.
    Cormican MG, Jones RN.
    Antimicrob Agents Chemother; 1997 Jan; 41(1):204-11. PubMed ID: 8980783
    [Abstract] [Full Text] [Related]

  • 3. Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study.
    Hoban DJ, Bouchillon SK, Johnson JL, Zhanel GG, Butler DL, Miller LA, Poupard JA, Gemifloxacin Surveillance Study Research Group.
    Diagn Microbiol Infect Dis; 2001 Jan; 40(1-2):51-7. PubMed ID: 11448564
    [Abstract] [Full Text] [Related]

  • 4. Comparative in vitro potency of gemifloxacin and fluoroquinolones against recent European clinical isolates from a global surveillance study.
    Hoban DJ, Bouchillon SK, Johnson JL, Zhanel GG, Butler DL, Miller LA, Poupard JA, Gemifloxacin Surveillance Study Research Group.
    Eur J Clin Microbiol Infect Dis; 2001 Nov; 20(11):814-9. PubMed ID: 11783700
    [Abstract] [Full Text] [Related]

  • 5. Comparative in vitro activity of gemifloxacin against gram-positive and gram-negative clinical isolates in Argentina.
    Lopez H, Stepanik D, Vilches V, Scarano S, Sarachian B, Mikaelian G, Finlay J, Sucari A.
    Diagn Microbiol Infect Dis; 2001 Aug; 40(4):187-92. PubMed ID: 11576792
    [Abstract] [Full Text] [Related]

  • 6. In vitro and in vivo antibacterial activities of DW286, a new fluoronaphthyridone antibiotic.
    Yun HJ, Min YH, Lim JA, Kang JW, Kim SY, Kim MJ, Jeong JH, Choi YJ, Kwon HJ, Jung YH, Shim MJ, Choi EC.
    Antimicrob Agents Chemother; 2002 Sep; 46(9):3071-4. PubMed ID: 12183275
    [Abstract] [Full Text] [Related]

  • 7. Comparative in vitro activities of five quinolone antibiotics, including gemifloxacin, against clinical isolates.
    Gönüllü N, Aktaş Z, Salcioglu M, Bal C, Ang O.
    Clin Microbiol Infect; 2001 Sep; 7(9):499-503. PubMed ID: 11678934
    [Abstract] [Full Text] [Related]

  • 8. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.
    Hoogkamp-Korstanje JA.
    J Antimicrob Chemother; 1997 Sep; 40(3):427-31. PubMed ID: 9338498
    [Abstract] [Full Text] [Related]

  • 9. Anti-streptococcal activity of SB-265805 (LB20304), a novel fluoronaphthyridone, compared with five other compounds, including quality control guidelines.
    Johnson DM, Jones RN, Erwin ME.
    Diagn Microbiol Infect Dis; 1999 Feb; 33(2):87-91. PubMed ID: 10091031
    [Abstract] [Full Text] [Related]

  • 10. In-vitro and in-vivo antibacterial activity of CFC-222, a new fluoroquinolone.
    Kim JH, Choi KH, Kim JW, Lee JH, Choi EC, Kim BK.
    J Antimicrob Chemother; 1998 Feb; 41(2):223-9. PubMed ID: 9533464
    [Abstract] [Full Text] [Related]

  • 11. Comparative in vitro activities of ciprofloxacin, gemifloxacin, grepafloxacin, moxifloxacin, ofloxacin, sparfloxacin, trovafloxacin, and other antimicrobial agents against bloodstream isolates of gram-positive cocci.
    Hardy D, Amsterdam D, Mandell LA, Rotstein C.
    Antimicrob Agents Chemother; 2000 Mar; 44(3):802-5. PubMed ID: 10681365
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of gemifloxacin (SB-265805, LB20304a): in vitro activity against over 6000 gram-positive pathogens from diverse geographic areas.
    Jones RN, Pfaller MA, Erwin ME.
    Int J Antimicrob Agents; 2000 Aug; 15(3):227-30. PubMed ID: 10926446
    [Abstract] [Full Text] [Related]

  • 13. Comparative in vitro activity of gemifloxacin.
    King A, May J, French G, Phillips I.
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():1-12. PubMed ID: 10824026
    [Abstract] [Full Text] [Related]

  • 14. In vitro susceptibility of 4903 bacterial isolates to gemifloxacin--an advanced fluoroquinolone.
    Blondeau JM, Hansen G, Metzler KL, Borsos S, Irvine LB, Blanco L.
    Int J Antimicrob Agents; 2003 Aug; 22(2):147-54. PubMed ID: 12927955
    [Abstract] [Full Text] [Related]

  • 15. In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer.
    Rolston KV, Ho DH, LeBlanc B, Streeter H, Dvorak T.
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():15-22. PubMed ID: 9222065
    [Abstract] [Full Text] [Related]

  • 16. In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones.
    Montanari MP, Prenna M, Mingoia M, Ripa S, Varaldo PE.
    Chemotherapy; 1998 Jun; 44(2):85-93. PubMed ID: 9551237
    [Abstract] [Full Text] [Related]

  • 17. In vitro activity of sparfloxacin, ciprofloxacin, ofloxacin, and other antibiotics against bloodstream isolates of gram-positive cocci.
    Rotstein C, Amsterdam D, Beam TR, Mandell LA, Gorzynski EA.
    Diagn Microbiol Infect Dis; 1993 Jul; 17(1):85-91. PubMed ID: 8395375
    [Abstract] [Full Text] [Related]

  • 18. In vitro and in vivo antibacterial activities of DW-224a, a new fluoronaphthyridone.
    Park HS, Kim HJ, Seol MJ, Choi DR, Choi EC, Kwak JH.
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2261-4. PubMed ID: 16723601
    [Abstract] [Full Text] [Related]

  • 19. Comparative in vitro activities of trovafloxacin (CP-99,219) against 445 gram-positive isolates from patients with endocarditis and those with other bloodstream infections.
    Endtz HP, Mouton JW, den Hollander JG, van den Braak N, Verbrugh HA.
    Antimicrob Agents Chemother; 1997 May; 41(5):1146-9. PubMed ID: 9145886
    [Abstract] [Full Text] [Related]

  • 20. Antimicrobial activity of LB20304, a fluoronaphthyridone, tested against anaerobic bacteria.
    Marco F, Barrett MS, Jones RN.
    J Antimicrob Chemother; 1997 Oct; 40(4):605-7. PubMed ID: 9372438
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.